6 -Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein, the loss of MGMT expression was commonly known due to hypermethylation of CpG islands in its promoter region. Overexpression of p53 protein may be associated with downregulated MGMT expression in brain tumors. The aims of this study were to investigate the role of MGMT expression loss and its correlation with p53 overexpression in endometrial cancers. MGMT and p53 expression was examined in formalin-fixed, paraffin-embedded tissues from 36 endometrial cancer cases using immnunohistochemical staining. The loss of MGMT expression was detected in 11 (30.6%) out of the 36 endometrial cancers and p53 immunoreactivity was detected in 23 (63.9%) out of the 36 endometrial cancers. Ten (90.9%) of the 11 cases with negative MGMT immunoreactivity showed positive p53 expression, so the loss of MGMT expression was significantly associated with the p53 overexpression (P=0.03). These findings suggest that the loss of MGMT expression may be one of factors capable of p53 overexpression in endometrial cancer. Further studies are needed to define the relation between MGMT and p53 for examining the mechanisms of tissue-specific MGMT expression. (J Cancer Prev 2013;18:351-354) 
-Methylguanine-DNA methyltransferase (MGMT) is a DNA repair protein that protects cells against the carcinogenic and cytotoxic effects of alkylating agents. 1 MGMT activity has been determined in various types of tumors, and was found to be relatively high in colon, ovary, breast and brain cancers. 2, 3 The lack of MGMT expression may be related to the development of gliomas, 4 non-small cell lung cancers, 5 and colon cancers. 6, 7 In the absence of MGMT activity, O 6 -alkylguanine mispairs with thymine during DNA replication and results in guanine-cytosine to adenine-thymine transitions. 6, 8 Other studies that showed loss of MGMT protein expression associated with methylation in diffuse large B cell lymphoma and colorectal and brain tumors. Tumor suppressor gene p53 plays an important role in the cell cycle, DNA damage, cell death and cell differentiation, and it is commonly mutated in human tumors. 9 Several studies have suggested the involvement of p53 protein in the expression of the MGMT gene. There are studies reported that MGMT gene expression was significantly lower in p53 altered tumors, 4 and MGMT promoter methylation may increase the occurrence of p53 mutation in lung cancer. 10 Other studies reported that wild-type p53
acts as an inhibitor of MGMT gene expression.
11
To the best of our knowledge, the relationship between MGMT and p53 expression in tissues of endometrial cancer
has not yet been studied in Korea. So we investigated the expression patterns of MGMT and p53 using immunohistochemistry to elucidate the tissues-specific relationship between MGMT and p53 expressions in endometrial cancers.
MATERIALS AND METHODS 
Immunohistochemical analysis
Immunohistochemical study for MGMT and p53 was performed on the formalin-fixed, paraffin-embedded, 4 μm thick tissue section using the avidin-biotin-peroxidase complex method. Deparaffinization of all the sections was performed through a series of xylene baths, and rehydration was performed with a series of graded alcohol solutions. To enhance immunoreactivity, microwave antigen retrieval was performed at 750 W for 30 min in and Gill's hematoxylin counterstain was applied.
Interpretation of immunohistochemical analysis
All the slides were evaluated without knowledge of any of the clinicopathologic data. Immunoreactivity for MGMT expression was defined by presence of nuclear and cytoplasmic staining and that for p53 expression was defined by presence of nuclear staining. The percentage scoring of the immunoreactive tumor cells was categorized into four groups: 0 (0%), 1 (1-10%), 2 (11-50%), and 3 (＞50%).
The staining intensity was also categorized into four groups: 0 (negative), 1 (weak), 2 (moderate), and 3 (strong). all the other scores were considered negative.
Statistical analysis
Statistical analysis was performed using SPSS for Windows Standard version 19.0 (SPSS, Chicago, IL, USA). Fisher exact test was performed to assess the relationship between the expression patterns of MGMT and p53. A P value less than 0.05 was considered to be statistically significant.
RESULTS
The loss of MGMT expression was detected in 11 (30.6%) out of the 36 endometrial cancers, and p53 immunoreactivity was detected in 23 (63.9%) out of the 36 endometrial cancers. Ten (90.9%) of the 11 cases with negative MGMT immunoreactivity showed positive p53 expression, whereas 1 (9.1%) of the 11 cases with negative MGMT immunoreactivity showed negative p53 expression.
So the loss of MGMT expression was significantly associated with the p53 overexpression (P=0.03) ( Table 1 , Fig. 1 ). -Methylguanine-DNA methyltransferase (MGMT) and p53 in endometrial cancer tissues; MGMT showed a negative nuclear and cytoplasmic immunoreactivity (A, ×400), p53 showed a positive nuclear immunoreactivity (B, ×400). 
DISCUSSION
Loss of MGMT expression has been reported to have a significantly role in carcinogenesis in various organs. 4 In this study, the loss of MGMT expression was detected in 11 (30.6%) out of the 36 endometrial cancers. There are studies that a lack of MGMT expression may be related to guanine to adenine mutation, and may be related to the development of gliomas, 4 non-small cell lung cancers, 5 and colonic cancers. 6, 7 However, other studies have been reported that the lack of MGMT expression in not commonly due to mutation, deletion, or rearrangement of the MGTM gene. 12 Hypermethylation of CpG islands in its promoter region is the most important mechanism. immuno-positivity may be strong predictors of breast cancer survival. 15 However, other studies that wild-type p53 is accompanied by lower MGMT protein expression. 
